Sk Chemicals Co., Ltd.

Dongwoo Syntech Co., Ltd

Sk Bioscience Co., Ltd.

Su-Jin Park

Hun Rae Kim

Jin-Hwan Shin

Mahn-Hoon Park

Hun Sung Kim

Myeong-Ju Noh

Ji-Hye Yang

Seon-Young Yang

Dong-Soo Ham

Chun-Rim Oh

Young-Deuck Kim

Provided is an immunogenic composition comprising 15 different polysaccharide-protein conjugates. Each of the conjugates comprises a capsular polysaccharide prepared from different serotypeconjugated to a carrier protein, that is, serotypes 1, 2, 3, 4, 5, 6A, 6B, 7F, 9N, 9V, 14, 18C, 19A, 19F and 23F. An immunogenic composition formulated into a vaccine comprising an aluminum-based adjuvant increases application range with respect to pneumococcal diseases in infants and children.

Polyvalent pneumococcal polysaccharide-protein conjugate composition

Provided is an immunogenic composition comprising 13 different polysaccharide-protein conjugates. Each of the conjugates comprises a capsular polysaccharide prepared from a different serotypeconjugated to a carrier protein, that is, 12 serotypes selected from the group consisting of 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F and serotype 2 or 9N. The immunogenic composition formulated into a vaccine comprising an aluminum-based adjuvant increases coverage with respect to pneumococcal diseases in infants and children.

Multivalent pneumococcal polysaccharide-protein conjugate composition

The present invention provides an improved method of producing a capsular polysaccharide having a pneumococcal serotype. The method according to the present invention includes a step of additionally culturing bacterial cells producing a pneumococcal serotype without pH adjustment, thereby removing a protein precipitation process by acidification with a pH adjuster.

Production method for capsular polysaccharide having pneumococcal serotype

Disclosed is a method for preparing 2'-deoxy-2&#x2032;,2&#x2032;-difluorocytidine of Formula I comprising, preparing an optically pure 3R-hydroxypropane amide compound of Formula VIII from an optical ester compound of Formula IX using an optically active chiral amine, preparing an optically pure D-erythro-2,2-difluoro-2-deoxy-1-oxoribose compound of Formula V from the compound of Formula VIII, glycosylating the compound of Formula V with a nucleobase to prepare the 2&#x2032;-deoxy-2&#x2032;,2&#x2032;-difluorocytidine of Formula I as a &#x3b2;-nucleoside. With the present invention, it is possible to prepare an optically pure compound of Formula I in a high purity and a high yield. In the Formulae, Rand Rare protecting groups and are each independently benzoyl, 4-methylbenzoyl, 3-methylbenzoyl, 4-cyanobenzoyl, 3-cyanobenzoyl, 4-propylbenzoyl, 2-ethoxybenzoyl, 4-t-butylbenzoyl, 1-naphthoyl or 2-naphthoyl, R, Rand Rare each independently C-Calkyl, Ris methyl or ethyl, Ris hydrogen, methyl or methoxy.

Process for preparing 2'-deoxy-2&#x2032;, 2&#x2032;-difluorocytidine

Growing community of inventors

Seongnam-si, South Korea

Su-Jin Park